Clinical trial
A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination With the ATR Inhibitor Tuvusertib (M1774)
NCT05687136 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination With the ATR Inhibitor Tuvusertib (M1774)
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- June 7, 2024
- Completion date
- August 31, 2027
- Enrollment
- 66 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
advanced malignant solid neoplasm, metastatic malignant solid neoplasm, unresectable malignant solid neoplasm